FDA Approves G1 Therapeutics’ COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Press/Media

Period14 Feb 2021

Media coverage

1

Media coverage

  • TitleFDA Approves G1 Therapeutics’ COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
    Media name/outletFirstWord Pharma
    Country/TerritoryUnited States
    Date14/02/21
    URLwww.firstwordpharma.com/node/1800647
    PersonsWilliam Roberts
View all 1
View less